Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2019
Reporting Period: Quarter ended June 30, 2019
Status: Emerging Growth Company
This filing serves as a notification that the Company issued a press release and presentation regarding its financial results for the quarter ended June 30, 2019. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) and is not explicitly detailed within the body of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release furnished as Exhibit 99.1.
Material Changes
No specific material changes or comparative financial data versus prior periods are disclosed in the text of this filing. Investors must refer to the incorporated press release for period-over-period analysis.
Guidance, Outlook, and Risks
- Management Commentary: The Company conducted an investor conference call on August 13, 2019, utilizing the presentation furnished as Exhibit 99.2.
- Regulatory Disclosure: The information in Items 2.02 and 7.01, including the press release and presentation, is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Guidance: No specific forward-looking guidance or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2019 revenue, net loss, and cash position figures.
- Review Exhibit 99.2 (Presentation) for management's outlook and strategic updates discussed during the August 13, 2019 conference call.
- Verify the Company's status as an Emerging Growth Company and its election to use the extended transition period for new accounting standards.
- Confirm that the financial data in the press release is not automatically incorporated by reference into other SEC filings without specific citation.